METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF OPHTHALMIC DISORDERS

The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant. 1. A method of treating an ophthalmic disorder in a patient , said method comprising ophthalmically administering prednisolone or prednisolone acetate and cyclosporine A , wherein said disorder is selected from the group consisting of allergic conjunctivitis and dry eye.2. The method of wherein prednisolone or prednisolone acetate is administered at a concentration of 0.12% and said cyclosporine A is administered at a concentration of 0.01% or 0.02%.3. The method of claim 2 , wherein said ophthalmic disorder is dry eye.4. The method of claim 2 , wherein said ophthalmic disorder is allergic conjunctivitis.5. The method of claim 1 , wherein said cyclosporine A is administered at a concentration of 0.01%.6. The method of claim 1 , wherein said cyclosporine A is administered at a concentration of 0.02%.7. The method of claim 1 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are administered as a single composition.8. The method of claim 7 , wherein said composition is a solution claim 7 , gel claim 7 , ointment claim 7 , suspension claim 7 , emulsion claim 7 , or solid insert.9. The method of claim 7 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are the sole active ingredients of said composition. This application is a divisional application of U.S. application Ser. No. 11/594,428, filed Nov. 8, 2006, which claims benefit of U.S. Provisional Application No. 60/735,989, filed Nov. 9, 2005, each of which is hereby incorporated by reference.The invention relates to the treatment of ophthalmic disorders.Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post- ...

METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF OPHTHALMIC DISORDERS

The invention features methods, kits, and compositions for the treatment of ophthalmic disorders. The compositions include a corticosteroid in combination with a non-steroidal immunophilin-dependent immunosuppressant. 1. A method of treating an ophthalmic disorder in a patient , said method comprising ophthalmically administering prednisolone or prednisolone acetate and cyclosporine A , wherein said disorder is selected from the group consisting of allergic conjunctivitis and dry eye.2. The method of wherein prednisolone or prednisolone acetate is administered at a concentration of 0.12% and said cyclosporine A is administered at a concentration of 0.01% or 0.02%.3. The method of claim 2 , wherein said ophthalmic disorder is dry eye.4. The method of claim 2 , wherein said ophthalmic disorder is allergic conjunctivitis.5. The method of claim 1 , wherein said cyclosporine A is administered at a concentration of 0.01%.6. The method of claim 1 , wherein said cyclosporine A is administered at a concentration of 0.02%.7. The method of claim 1 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are administered as a single composition.8. The method of claim 7 , wherein said composition is a solution claim 7 , gel claim 7 , ointment claim 7 , suspension claim 7 , emulsion claim 7 , or solid insert.9. The method of claim 7 , wherein said prednisolone or prednisolone acetate and said cyclosporine A are the sole active ingredients of said composition. This application is a continuation application of U.S. application Ser. No. 13/305,391 filed Nov. 28, 2011, which is a divisional application of U.S. application Ser. No. 11/594,428, filed Nov. 8, 2006, which claims benefit of U.S. Provisional Application No. 60/735,989, filed Nov. 9, 2005, each of which is hereby incorporated by reference.The invention relates to the treatment of ophthalmic disorders.Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder ...

COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiments, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein (e.g., do not show detectable binding in mammalian cells absent the compound). In some embodiments, provided compounds “re-program” presenter protein binding to greatly enhance interaction with a particular target with which it may have some interaction absent the compound. Interactions achieved through such reprogramming result in an ability to modulate the activity of these new targets. 1. A macrocyclic compound , or a pharmaceutically acceptable salt thereof , comprising 14 to 40 ring atoms , said compound comprising:(a) a mammalian target protein interacting moiety; and(b) a presenter protein binding moiety;wherein said compound and a presenter protein form a complex that specifically binds to a target protein, and each of said compound and said presenter protein do not substantially bind to said target protein in the absence of forming said complex; orsaid compound and a presenter protein form a complex that binds to a ...

METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins. 1. A compound comprising:(a) an FKBP binding moiety or cyclophilin binding moiety; and(b) a cross-linking group, wherein the cross-linking group is a sulfhydryl-reactive cross-linking group, an amino-reactive cross-linking group, a carboxyl-reactive cross-linking group, a carbonyl-reactive cross-linking group, or a triazole-forming cross-linking group.2. The compound of claim 1 , wherein the cross-linking moiety is a mixed disulfide claim 1 , a maleimide claim 1 , a vinyl sulfone claim 1 , a vinyl ketone claim 1 , or an alkyl chloride.3. The compound of claim 1 , wherein the interaction between the FKBP binding moiety or cyclophilin binding moiety and FKBP or cyclophilin is non-covalent.4. The compound of claim 1 , wherein the FKBP binding moiety is an FKBP binding moiety capable of binding FKBP12 claim 1 , FKBP12.6 claim 1 , FKBP13 claim 1 , FKBP25 claim 1 , FKBP51 claim 1 , FKBP52 claim 1 , or the cyclophilin binding moiety is a cyclophilin binding moiety capable of binding PP1A claim 1 , CYPB claim 1 , CYPC claim 1 , CYP40 claim 1 , CYPE claim 1 , CYPD claim 1 , NKTR claim 1 , SRCyp claim 1 , CYPH claim 1 , CWC27 claim 1 , CYPL1 claim 1 , CYP60 claim 1 , CYPJ claim 1 , PPIL4 claim 1 , PPIL6 claim 1 , RANBP2 claim 1 , or PPWD1.5. The compound of claim 1 , wherein the FKBP binding moiety or cyclophilin binding moiety is a selective FKBP or cyclophilin binding moiety.6. The compound of claim 1 , wherein the FKBP binding moiety or cyclophilin binding moiety is a non-selective FKBP or cyclophilin binding moiety.9. The compound of claim 1 , wherein the FKBP ...

METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins. 2. The compound of claim 1 , wherein the cross-linking group is a mixed disulfide claim 1 , a maleimide claim 1 , a vinyl sulfone claim 1 , a vinyl ketone claim 1 , or an alkyl chloride.3. The compound of claim 1 , wherein the interaction between the cyclophilin binding moiety and cyclophilin is non-covalent.4. The compound of claim 1 , wherein the cyclophilin binding moiety is a cyclophilin binding moiety capable of binding PP1A claim 1 , CYPB claim 1 , CYPC claim 1 , CYP40 claim 1 , CYPE claim 1 , CYPD claim 1 , NKTR claim 1 , SRCyp claim 1 , CYPH claim 1 , CWC27 claim 1 , CYPL1 claim 1 , CYP60 claim 1 , CYPJ claim 1 , PPIL4 claim 1 , PPIL6 claim 1 , RANBP2 claim 1 , or PPWD1. This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.The vast majority of small molecule drugs act by binding a functionally important pocket on a target protein, thereby modulating the activity of that protein. For example, the cholesterol-lowering drugs statins bind the enzyme active site of HMG-CoA reductase, thus preventing the enzyme from engaging with its substrates. The fact that many such drug/target interacting pairs are known may have misled some into believing that a small molecule modulator could be discovered for most, if not all, proteins provided a reasonable amount of time, effort, and resources. This is far from the case. Current estimates hold that only about 10% of all human proteins are targetable by small molecules. The other 90% are currently considered refractory or intractable ...

METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins. 2. The compound of claim 1 , wherein the cross-linking group is a mixed disulfide claim 1 , a maleimide claim 1 , a vinyl sulfone claim 1 , a vinyl ketone claim 1 , or an alkyl chloride.3. The compound of claim 1 , wherein the interaction between the FKBP binding moiety and FKBP is non-covalent.4. The compound of claim 1 , wherein the FKBP binding moiety is a FKBP binding moiety capable of binding FKBP12 claim 1 , FKBP12.6 claim 1 , FKBP13 claim 1 , FKBP25 claim 1 , FKBP51 claim 1 , or FKBP52. This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference.The vast majority of small molecule drugs act by binding a functionally important pocket on a target protein, thereby modulating the activity of that protein. For example, the cholesterol-lowering drugs statins bind the enzyme active site of HMG-CoA reductase, thus preventing the enzyme from engaging with its substrates. The fact that many such drug/target interacting pairs are known may have misled some into believing that a small molecule modulator could be discovered for most, if not all, proteins provided a reasonable amount of time, effort, and resources. This is far from the case. Current estimates hold that only about 10% of all human proteins are targetable by small molecules. The other 90% are currently considered refractory or intractable toward small molecule drug discovery. Such targets are commonly referred to as “undruggable.” These undruggable targets include a vast and largely untapped reservoir of medically important ...

COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiments, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein (e.g., do not show detectable binding in mammalian cells absent the compound). In some embodiments, provided compounds “re-program” presenter protein binding to greatly enhance interaction with a particular target with which it may have some interaction absent the compound. Interactions achieved through such reprogramming result in an ability to modulate the activity of these new targets. 4. The compound of claim 1 , wherein Xis O.5. The compound of claim 1 , wherein Xis NR.6. The compound of claim 5 , wherein Ris hydrogen.7. The compound of claim 1 , wherein Ris optionally substituted —(C-Calkylene)—Caryl.8. The compound of claim 7 , wherein Ris an optionally substituted phenethyl.9. A presenter protein/compound complex comprising the compound of and a presenter protein.10. The complex of claim 9 , wherein the presenter protein is FKBP12 claim 9 , FKBP12.6 claim 9 , FKBP25 claim 9 , or FKBP4.11. A pharmaceutical composition ...

Storm water dispersing system having multiple arches

In a system for dispersing stormwaters beneath the earth surface, a pair of arch shaped molded plastic chambers (20) lie parallel each to the other upon a bed of gravel and are covered with soil. A bridge cover (50) spans the space (36) between the sidewalls (28) of the adjacent chambers, to keep the soil above from entering. Preferably, abutting base flanges (30) establish the chamber spacing which fits the bridge cover and also protect gravel at the bottom of the space from erosion. Stormwater is preferably delivered to the space (36), to then flow through sidewall perforations (29) into the chambers' interiors where it is stored and gradually dispersed into the earth. Debris settles in the pocket (31) at the bottom of the space (36) and is removed by a perforated pipe (90) lying in the space. Chambers have high aspect ratios, of 0.8 to 1 or more, and steep sidewall angles, of less than 15 degrees.

Methods and reagents for the treatment of metabolic disorders

The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

Methods, compositions, and kits for the treatment of pain

The invention features methods, compositions, and kits for the treatment of pain.

Storm water dispersing system having multiple arches

In a system for dispersing stormwaters beneath the earth surface, a pair of arch shaped molded plastic chambers (20) lie parallel each to the other upon a bed of gravel and are covered with soil. A bridge cover (50) spans the space (36) between the sidewalls (28) of the adjacent chambers, to keep the soil above from entering. Preferably, abutting base flanges (30) establish the chamber spacing which fits the bridge cover and also protect gravel at the bottom of the space from erosion. Stormwater is preferably delivered to the space (36), to then flow through sidewall perforations (29) into the chambers' interiors where it is stored and gradually dispersed into the earth. Debris settles in the pocket (31) at the bottom of the space (36) and is removed by a perforated pipe (90) lying in the space. Chambers have high aspect ratios, of 0.8 to 1 or more, and steep sidewall angles, of less than 15 degrees.

Method, composition, and kit for treatment of medical condition

【課題】免疫炎症性疾患、眼科疾患、筋骨格障害もしくはそれに伴う疼痛、歯周病、または血清CRPレベルの上昇と関連する疾患に対する改善された治療薬および治療法の提供。 【解決手段】治療を必要とする患者への投与時に、免疫炎症性疾患、眼科疾患、筋骨格障害もしくはそれに伴う疼痛、歯周病、または血清CRPレベルの上昇と関連する疾患もしくは状態を治療するのに併せて十分な量で、特定のペアから選択される薬物ペアを含む組成物。 【選択図】なし

Methods and Reagents for the Treatment of Metabolic Disorders

Oppfinnelsen angår sammensetninger, fremgangsmåter og kit for behandling av metabolske forstyrrelser slik som diabetes og overvekt. Sammensetningene omfatter en kombinasjon av bezafibrat og diflunisal, eller analoger derav.

Leaching system conduit with interlocking end joint

A conduit for dispersing or gathering liquids in the earth has an arch shape cross section and alternating peak and valley corrugations along its length, with cantilever legs extending from one end to interact with the mating portion of a like conduit. The legs, along with a shiplap joint having flange discontinuities for manufacturability, provide a superior rigid joint when the conduits are mated and buried beneath the earth and subjected to vertical loads.

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1 ) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Leaching chamber with perforated web sidewall

Faceted end cap for leaching chamber

A molded thermoplastic domed end cap (20), for attachment to the end of an arch shape cross section leaching chamber or stormwater chamber, has a multiplicity of buttresses (38), to provide facet surfaces where pipe connections may be made. The essentially planar surface portions have tear out or cut out regions (34), for pipe openings. The buttresses (38) face in different directions, relative to the longitudinal axis (X) of the end cap, to conveniently accommodate pipes running in different angular directions. Pipes, which pass through openings in the surfaces of the buttresses, are supported by molded in step-saddles (56, 52) of the buttresses. Molded in stops (44, 42) limit inward motion of pipes.

Formulations, conjugates, and combinations of drugs for the treatment of neoplasms

The invention provides formulations and structural modifications for phenothiazine compounds which result in altered biodistributions, thereby reducing the occurrence of adverse reactions associated with this class of drug.

Combinations for the treatment of proliferative diseases

Det beskrives kombinasjoner av medikamenter til behandlingen av proliferative sykdommer (f.eks. cancer). Det beskrives også fremgangsmåter for identifisering av nye kombinasjonsterapier til behandlingen av cancer og andre proliferative sykdommer.

Combinations of drugs for the treatment of neoplasms

Det beskrives en fremgangsmåte for behandling av en pasient som har en cancer eller annen neoplasme, ved å administrere pasienten to forbindelser samtidig eller innen 14 dagers mellomrom, i mengder som er tilstrekkelige til å behandle pasienten.

Combinations of drugs for the treatment of neoplasms

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient chlorpromazine or a chlorpromazine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Methods for the treatment of neoplasms

Methods, compositions, and kits for the treatment of medical conditions

The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.

Leaching chamber with perforated web sidewall

A molded plastic leaching chamber, for dispersing or collecting liquids in soil, has a corrugated arch shape. The sidewall of the chamber is comprised of alternating slot-perforated peaks and valleys connected by slot-perforated deep webs. The unit surface length of perforated sidewall is greater than the unit length of chamber. A combination of interrelated dimensions and angles provide high leaching capacity, strength, and capability to nest for shipment. The sidewall is reinforced by vertically running ribs; the perforated web is reinforced by zig-zag struts. Ribs and struts are shaped and positioned to minimize blockage of the slot openings and injection molding.

Storm water dispersing system having multiple arches

In a system for dispersing stormwaters beneath the earth surface, a pair of arch shaped molded plastic chambers (20) lie parallel each to the other upon a bed of gravel and are covered with soil. A bridge cover (50) spans the space (36) between the sidewalls (28) of the adjacent chambers, to keep the soil above from entering. Preferably, abutting base flanges (30) establish the chamber spacing which fits the bridge cover and also protect gravel at the bottom of the space from erosion. Stormwater is preferably delivered to the space (36), to then flow through sidewall perforations (29) into the chambers' interiors where it is stored and gradually dispersed into the earth. Debris settles in the pocket (31) at the bottom of the space (36) and is removed by a perforated pipe (90) lying in the space. Chambers have high aspect ratios, of 0.8 to 1 or more, and steep sidewall angles, of less than 15 degrees.

Combinations for the treatment of inflammatory skin disorders

Method, compositions, and kits for the treatment of medical conditions

Disclosed is a use of prednisolone or prednisolone acetate and cyclosporine A in the manufacture of a medicament for the treatment of an ophthalmic disorder in a patient, wherein said prednisolone or prednisolone acetate is formulated at a concentration between 0.05% and 0.12% and said cyclosporine A is formulated at a concentration between 0.001% and 0.049% and wherein said composition is suitable for ophthalmic administration. Also described are methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.

Gas-assisted injection molding of hollow ribbed article

Improvements in articles, made by gas assisted injection molding of polyethylene and other materials, such as large arch shaped subsurface leaching conduits, and the processes by which they are made, are disclosed. The improvements involve control of which portions are hollow and which are solid, and include a stepped rib, where the thinner upper rib portion is solid and the wider base is hollow; articles having corrugated surfaces strengthened by ribs on both sides, where the hollows of the opposing side ribs are connected through holes in the undulating walls; articles having ribs which are narrowed where they are solid, compared to their width where they are hollow; and, articles having thinned wall regions surrounding sprues, to avoid undesired hollowing during injection molding.

Combination of drugs for the treatment of neoplasms

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient pentamidine or a pentamidine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Combinations for the treatment of fungal infections

Methods for the treatment of neoplasms

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient a niclosamide, or a structural or functional analog thereof, and, optionally, one or more antiproliferative agents in an amount effective to inhibit the growth of the neoplasm.

Soft tissue implants and drug combination compositions, and use thereof

Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

Methods, compositions, and kits for the treatment of medical conditions

The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.

Leaching system conduit with high rigidity joint

A conduit for dispersing or gathering liquids in the earth has an arch shape cross section and alternating peak and valley corrugations along its length. A more rigid shiplap joint is formed between mating conduits by means of cantilever legs extending from the end of a conduit, forming a female pocket like space for the mating unit, and by having a continuous web on the peak corrugation adjacent the end. A sub-arch at the top of an overlapped valley end, to enable connection of a pipe to the conduit, is spaced apart from the web of the adjacent peak corrugation; there are multiple legs on either side of the sub-arch, with the sub-arch connected by webs to the adjacent legs, and by other webs to the peak corrugation.

Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1 ) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides compounds comprising a presenter protein binding moiety (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) or a target protein binding moiety and a cross-linker group; compositions of the compounds; their conjugates and complexes; and related methods for determining the structure of a complex or the interface in a complex therewith. In some embodiments, the target and/or presenter proteins are intracellular proteins.

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

Combination therapy for the treatment of neoplasms

The invention features methods, kits, and compositions for the treatment of cancer and other proliferative diseases.

Soft tissue implants and drug combination compositions, and use thereof

Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

Combination therapy for the treatment of neoplasms

The invention features compositions, methods, and kits for the treatment of neoplasms.

Combinations for the treatment of fungal infections

The invention features a method for treating or preventing fungal growth by contacting fungal cells with (I) an aromatic diamidine or analog thereof or a compound formula (I); and (ii) an aminopyridine, a quaternary ammonium compound, or a compound of formula (II) or (III) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit fungal growth.

Stormwater dispersing chambers

Combination of drugs for the treatment of neoplasms

Combination of drugs for the treatment of neoplasms

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient pentamidine or a pentamidine analog and an antiproliferative agent simultaneously or within 14 days of each other in amounts sufficient to treat the patient.

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.